<DOC>
	<DOCNO>NCT00320788</DOCNO>
	<brief_summary>This study examine effect intravitreally administer VEGF Trap patient wet AMD . The purpose trial ass ocular systemic safety tolerability repeat intravitreal dos VEGF Trap patient subfoveal choroidal neovascularization ( CNV ) due AMD .</brief_summary>
	<brief_title>Safety Efficacy Repeated Intravitreal Administration Vascular Endothelial Growth Factor ( VEGF ) Trap Patients With Wet Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>This double masked , prospective , randomize study five group approximately 30 patient meet eligibility criterion randomly assign balance ratio receive series intravitreal ( IVT ) injection VEGF Trap study eye 4- 12 -week interval 12-week period . After Week 12 , patient evaluate every 4 week . Patients remain study may eligible enter long-term extension study , continue receive VEGF Trap .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Subfoveal CNV secondary AMD . Central retinal ( include lesion ) thickness ≥ 300 µm measure Optical Coherence Tomography ( OCT ) . Early Treatment Diabetic Retinopathy Study ( ETDRS ) bestcorrected visual acuity 73 letter 34 letter . History vitreous hemorrhage within 4 week prior Day 1 . Aphakia . Significant subfoveal atrophy scarring . Prior treatment follow study eye : Subfoveal thermal laser therapy . Submacular surgery surgical intervention treatment AMD . Extrafoveal laser coagulation treatment within 12 week prior Day 1 . Photodynamic therapy ( PDT ) within 12 week prior Visit 2 ( Day 1 ) . Pegaptanib sodium ( Macugen ) within 8 week Visit 2 ( Day 1 ) . Juxtascleral steroid anecortave acetate within 24 week ( 6 month ) prior Visit 2 ( Day 1 ) . Intravitreal administration triamcinolone acetonide steroid within 24 week prior Visit 2 ( Day 1 ) , unless visible residue drug substance see vitreous cavity use indirect ophthalmoscopy . Prior systemic intravitreal treatment VEGF Trap , ranibizumab ( Lucentis ) bevacizumab ( Avastin ) . Presence condition laboratory abnormality , , opinion Investigator , would interfere assessment disease status/progression jeopardize patient 's appropriate participation Phase II study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Neovascular Age-Related Macular Degeneration</keyword>
</DOC>